177 Lu-DOTATATE Retreatment in Progressive Well-Differentiated NETs: Outcomes from the LUTHREE Prospective Study (EANM 2026) - Sep 29, 2026 - Abstract #OP-260; Pres time: Oct 18, 2026; 04:45 PM - 06:15 PM; Location: Hall G1; P2 | "Re-PRRT with [177Lu]-DOTATATE according to the LUTHREE risk-adapted study is effective and well tolerated in patients with progressive well-differentiated NETs. A PFS1 ≥36 months after I-PRRT appears to identify patients most likely to benefit from retreatment."
Clinical • Hematological Disorders • Neuroendocrine Tumor • Neutropenia • Solid Tumor • SSTR
|
|
M. Sansovini; S. Nicolini; I. Grassi; M. Celli; I. Marini; D. Valentina; A. Sarnelli; M. Monti; E. Giani; L. Vizza; F. Foca; P. Caroli; F. Matteucci
|